
Please try another search
Opyl Limited engages in the development of digital tools that enhance healthcare experience for patients in Australia. The company offers TrialKey, an AI-driven clinical trial optimization and success prediction platform, that simulate and optimize trial designs for pharmaceuticals, medical devices, alternative therapies, and novel conditions. It also provides TrialGen, an AI-powered tool streamlines clinical trial design process for biopharma, MedTech, government, and healthcare organizations. The company was formerly known as ShareRoot Limited and changed its name to Opyl Limited in December 2019. Opyl Limited was incorporated in 1994 and is based in Milsons Point, Australia.
Name | Age | Since | Title |
---|---|---|---|
Kirsten Daru | 47 | 2018 | Member of Advisory Board |
Damon Rasheed | - | 2019 | CTO & Executive Director |
Antanas Guoga | 50 | 2018 | Non-Executive Director |
Ari Scharg | - | - | Member of Advisory Board |
Paul-Olivier DeHaye | - | - | Member of Advisory Board |
Christopher A. Ciavarra | 53 | 2018 | Member of Advisory board |
Saurabh Jain | - | 2023 | Interim CEO & Executive Chairman |
Dimitrie Spiru Hugo Stephenson | 50 | 2023 | Board Advisor |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review